Bo Ahrén
81 – 90 of 398
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?
- Contribution to journal › Debate/Note/Editorial
-
Mark
Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial.
- Contribution to journal › Article
-
Mark
Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes.
- Contribution to journal › Debate/Note/Editorial
-
Mark
Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control.
- Contribution to journal › Article
-
Mark
High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial
- Contribution to journal › Article
- 2014
-
Mark
Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
(2014) In Diabetes therapy : research, treatment and education of diabetes and related disorders
- Contribution to journal › Article
-
Mark
Impact of glucose dosing regimens on modeling of glucose tolerance and β-cell function by intravenous glucose tolerance test in diet-induced obese mice.
- Contribution to journal › Article
-
Mark
Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.
- Contribution to journal › Article
-
Mark
Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function.
- Contribution to journal › Article
-
Mark
Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets.
- Contribution to journal › Article